Five things for pharma marketers to know: Monday, November 19, 2018
Florida sues Walgreens, CVS over opioids; Results from experimental peanut allergy study; AstraZeneca plans ahead for next CEO.
-
-
Industry, government square off over list prices in DTC ads
The pharma industry is set for a battle as the Trump administration and trade group PhRMA offer competing solutions to putting drug prices in TV ads. -
Brodeur Partners’ Lauren Levinson on transparency in healthcare proposals
With greater transparency of the cost and sale price of a drug must also come greater transparency of the inputs, ecosystem, and risk investment on which drug development relies. -
MM&M partners with Step Up on 2019 Hall of Femme
A portion of all proceeds from nominations will be donated to the nonprofit.
LATEST NEWS
Pfizer to resume price increases in January
The drugmaker will raise prices on 10% of its drug portfolio.
Five things for pharma marketers to know: Friday, November 16, 2018
Group of Takeda investors try to block Shire deal; FDA’s Gottlieb threatens to pull e-cigarettes completely; AstraZeneca’s immunotherapy fails late-stage lung cancer trial.
Five things for pharma marketers to know: Thursday, November 15, 2018
FDA imposes restrictions on e-cigarette sales; Pfizer launches biosimilar to treat anemia; J&J cleared of liability in one talc case.
Healthcare execs optimistic about AI, survey says
Healthcare leaders expect to spend an average of $32 million implementing artificial intelligence into their business.
Five things for pharma marketers to know: Wednesday, November 14, 2018
Juul suspends flavored vape sales in retail stores, quits social media; Google health unit to absorb DeepMind AI health division; Indegene launches digital agency.
Digital growth is killing creative quality, say most marketers
A new study suggests creative departments are struggling to keep up data-driven advertising.
Bid-process meddling investigation closed for Omnicom, MDC, Publicis, IPG and WPP
The shops were being probed after independent production companies accused advertising agencies of improper practices.
The path to accountability in POC
There has been more intrigue and discussion about the point-of-care environment over the past 18 months than in the last decade combined — and the news keeps on coming.
Fear and hope help healthcare marketing trigger action
People are more inclined to change their lives for the better when content is motivational instead of based on shock-value, study finds.
Five things for pharma marketers to know: Tuesday, November 13, 2018
Amarin CEO defends Vascepa trial results; Tech companies meet to discuss opioid epidemic; GSK to launch clinical program for pancreatic cancer.
